Author

A. Vaysse

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1 Organism:E. coli· 1 Approach:experimental assay· 1

Frequent Co-Authors

A. Mettouchi· 2 shared D. Mestivier· 2 shared E. Lemichez· 2 shared I. Sobhani· 2 shared M. Chamaillard· 2 shared T. Pedron· 2 shared A. Biton· 1 shared A. Doukani· 1 shared

Activity by Year

2022-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 34 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Mettouchi

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

The Colibactin-Producing Escherichia coli alters the tumor microenvironment to immunosuppressive lipid overload facilitating colorectal cancer progression and chemoresistance.

N. de Oliveira Alves, G. Dalmasso, D. Nikitina, A. Vaysse, R. Ruez, L. Ledoux, T. Pedron, E. Bergstein, O. Boulard, L. Autier, S. Allam, L. Motreff, P. Sauvanet, D. Letourneur, J. Gagniere, , M. Chamaillard

This study shows that Colibactin-producing Escherichia coli creates an immunosuppressive lipid-rich tumor microenvironment that promotes colorectal cancer progression and chemoresistance.

bioRxiv · Mar 13, 2023 · PreprintCancer Biology

IRF8 regulates efficacy of therapeutic anti-CD20 monoclonal antibodies

L. Grzelak, F. Roesch, A. Vaysse, A. Biton, F. Porrot, P.-H. Commere, C. Planchais, H. Mouquet, M. Vignuzzi, T. Bruel, O. Schwartz

This study identifies IRF8 as a regulator of CD20 expression and anti-CD20 antibody efficacy through CRISPR screening and functional validation in B cells.

bioRxiv · Jun 9, 2022Immunology

Parvimonas micra, an oral pathobiont associated with colorectal cancer, epigenetically reprograms human primary intestinal epithelial cells

E. Bergsten, D. Mestivier, F. Donnadieu, T. Pedron, C. Barau, L. Tsoumtsa, A. Mettouchi, E. Lemichez, O. Gorgette, M. Chamaillard, A. Vaysse, S. Volant, A. Doukani, P. J. Sansonetti, I. Sobhani, G. Nigro

This study shows that Parvimonas micra phylotype A alters DNA methylation and gene expression in intestinal epithelial cells, potentially contributing to colorectal cancer.

bioRxiv · May 14, 2022 · PreprintMicrobiology